Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

  1. Mok, T.S.
  2. Cheng, Y.
  3. Zhou, X.
  4. Lee, K.H.
  5. Nakagawa, K.
  6. Niho, S.
  7. Chawla, A.
  8. Rosell, R.
  9. Corral, J.
  10. Migliorino, M.R.
  11. Pluzanski, A.
  12. Noonan, K.
  13. Tang, Y.
  14. Pastel, M.
  15. Wilner, K.D.
  16. Wu, Y.-L.
Revue:
Drugs

ISSN: 1179-1950,  0012-6667

Année de publication: 2021

Volumen: 81

Número: 2

Pages: 257-266

Type: Article

DOI: 10.1007/S40265-020-01441-6 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus